Press releases
* (R) = Regulatory press releases
Mar 14, 2024
(R) Cantargia presents new human data further supporting CAN10 in the treatment of systemic sclerosis
Mar 5, 2024
Cantargia reports new preclinical data on antitumor effects of nadunolimab in pancreatic cancer
Feb 22, 2024
(R) Cantargia publishes Year-End Report for 2023
Feb 20, 2024
(R) Cantargia reports US regulatory approval to start pancreatic cancer phase IIb trial with nadunolimab
Feb 7, 2024
Invitation to presentation of Cantargia’s year-end report 2023 on February 22 at 3.00 p.m. CET
Nov 30, 2023
